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Abstract 
Leishmaniasis is a neglected vector-borne tropical infection considered to be a disease of the poor. Concentrated in poverty-stricken countries 
within Southeast Asia, East Africa, and Latin America, it is also endemic in several Mediterranean countries. The management of the 
heterogeneous syndromes determined by parasites belonging to the genus Leishmania is particularly difficult in developed, non-endemic 
countries owing to the unfamiliarity of physicians with clinical symptoms, diagnostic possibilities, and available treatment options. 
Therefore, travelers and other people who may be exposed to sand flies in endemic areas should receive counseling regarding leishmaniasis 
and appropriate protective measures. Serological diagnosis is rarely used for cutaneous and mucocutaneous diseases, but it is the most 
commonly used technique for visceral leishmaniasis. The drugs used to treat this last disease are expensive and sometimes have toxic side 
effects. 
This review highlights the diagnostic, chemotherapeutic, and immunizing strategies to control leishmaniasis, though no human vaccine is 
commercially available currently owing to the complexity of the cellular immune response to this parasite. 
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Introduction 
Leishmaniasis is a neglected vector-borne tropical 
infection that is considered to be a disease of the poor 
[1].  
Concentrated in poverty-stricken countries within 
Southeast Asia, East Africa, and Latin America, it is 
also endemic in several Mediterranean countries [2]. 
On a global scale, ∼350 million people live in areas 
characterized by active transmission of Leishmania, 
with 14 million people directly affected by the disease 
[2]. There are three main types of leishmaniasis: 
visceral (kala-azar), the most important disease; 
cutaneous, the most common; and mucocutaneous. 
Among parasitic diseases, mortality from 
leishmaniasis is second only to malaria and, in terms 
of disability-adjusted life years (DALYs), the third-
most common cause of morbidity after malaria and 
schistosomiasis, with children under 15 years of age 
suffering most of the disease burden. International 
traveling has caused an increase of leishmaniasis cases 
in non-endemic countries, making the recognition of 
this parasitic infection important [4]. Moreover, the 
increase of immunosuppressed individuals, secondary 
to human immunodeficiency virus (HIV) infection and 
post-transplant and chemotherapeutic agents, has 
resulted in an increase of visceral leishmaniasis in 
Europe [5,6]. Kala-azar, the most deadly parasitic 
disease after malaria, spread by sand fly bites, afflicts 
hundreds of thousands of the world’s poorest people in 
tropical countries. This vector-borne protozoan 
infection has clinical spectrum ranges from 
asymptomatic infection to fatal visceral leishmaniasis. 
As reported by Alvar et al. [6], the number of 
cases of visceral leishmaniasis (VL) is calculated to be 
as high as 0.2–0.4 million people per year, with more 
than 90% of these occurring in India, Bangladesh, 
Sudan, Ethiopia, and Brazil, with a mortality estimated 
at 10%–20%, especially in poor areas. Cutaneous 
leishmaniasis (CL), considered by the World Health 
Organization (WHO) a category 1 emerging and 
uncontrolled disease [7], occurs mainly in the 
Mediterranean littoral, the Americas, and western 
Asia; up to 75% of these cases are found in Brazil, 
Syria, and Afghanistan. Approximately 35,000 cases 
of mucosal leishmaniasis occur annually, mainly in 
Brazil, Peru, and Bolivia [2]. In European countries, 
only two Leishmania species are endemic: L. 
infantum, responsible for zoonotic cutaneous and 
systemic disease within the Mediterranean region, 
with a reservoir in the domestic dog; and L. tropica, 
causing sporadic cases of anthroponotic cutaneous 
disease mainly in Greece. Autochthonous transmission 
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has been reported in Portugal, Spain, France, Italy, 
Greece, Malta, Cyprus, Croatia, Albania, Bulgaria, and 
Turkey. Most are sporadic endemic diseases, but 
recent outbreaks of leishmaniasis have occurred in 
Spain and Italy [8,9]. A recent case described by de 
Silva et al. [10] emphasizes the importance of a 
differential diagnosis in the presence of compatible 
skin lesions following foreign travel. 
VL is hypoendemic in Mediterranean countries; 
cases in this area account for 5%–6% of the global 
burden. It does not necessarily lead to clinical disease; 
most infections remain asymptomatic, but malnutrition 
and immune suppression, notably HIV, predispose to 
clinical diseases [5]. Cases of Leishmania/HIV co-
infection have been reported in the Mediterranean 
region, mainly in France, Italy, Portugal, and Spain 
[11]. Since highly active antiretroviral therapy was 
introduced in 1997, a marked decrease in the number 
of co-infected cases both in these regions and in India 
have been reported [12]. VL is a rare disease in solid-
organ transplant recipients. Clemente et al. [13], in a 
multicenter study, determined the risk factors and 
outcomes of VL in these patients. They observed that 
diagnosis was frequently delayed and relapses were 
common after treatment. 
Despite a tentative estimate of mortality of 
20,000–40,000 VL deaths per year, leishmaniasis 
belongs to the group of neglected tropical diseases. In 
2007, the World Health Assembly approved a 
resolution on the control of leishmaniasis, and the 
WHO established control programs. In 2010, an expert 
committee concluded that adequate worldwide 
leishmaniasis control is feasible but that there is a 
crucial lack of political commitment and international 
cooperation. This disease remains a major neglected 
tropical disease, and a strategic framework for its 
control in the WHO European region has been recently 
applied [14]. 
These intracellular protozoa have a complex 
digenetic life cycle, requiring a susceptible vertebrate 
host and a permissive insect vector, which allow their 
transmission. Diniz et al. [15] emphasized the 
importance of animal reservoirs in facilitating 
transmission of VL in densely populated urban areas 
in Brazil, and recently, Turchetti et al. [16] discussed 
the role of sexual and vertical transmission of this 
disease in canine populations playing an important 
role in the maintenance of VL. 
As a result of a long host-parasite co-evolutionary 
process, Leishmania spp. has developed different 
immunomodulatory strategies that are essential for the 
establishment of infection. Understanding the 
mechanisms associated with immune evasion and 
disease progression is essential for the development of 
novel therapies and vaccine approaches. Cecilio et al. 
[17] recently revised how the parasite manipulates cell 
death and immune responses to survive. The parasite 
can alter the maturation process of the phagolysosome, 
modulate cytokine and chemokine production by host 
cells, impairing cell function, to enter host cells and 
successfully differentiate and infect. 
A review concerning outbreaks in Israel over a 
recent 13-year period revealed an expansion of CL 
illness in southern, central, and northern areas of the 
country [18]. Therefore, studies of the responsible 
factors and a greater degree of public alertness are 
necessary. Zoonotic CL due to L. major is still a 
serious public health problem also in Tunisia. 
Researchers comparing the prevalence and risk factors 
in old and new foci using leishmanin skin test (LST) in 
central Tunisia observed [19] that the overall 
prevalence of LST positivity was 57%, and was 
significantly higher in the old focus than in the 
emerging foci. In 2012, a CL outbreak was observed 
among Syrian refugees in Lebanon [20] due to L. 
tropica and L. major infection in 85% and 15% of 
patients, respectively. These infections were cured in 
82% of the cases by megulamine antimonite therapy 
for three months. An unusual presentation of imported 
L. infantum CL, diagnosed in an Australian who had 
traveled in Italy 19 years before, has been reported 
[21], supporting the importance of parasite persistence 
evaluation in the diagnosis of this infection. 
Climate changes in Europe have increased the 
spread of new vectors. In northern Italy, leishmaniasis 
has been associated with climatic conditions that favor 
the development of the vector Phlebotomus 
perniciosus [22,23]. The increase of VL cases is also 
related to immunodepression and other variables, such 
as the increase of international travel, migration, and 
trade, which present the risk of importing parasites, 
vectors, and infections [24]. The main area for the 
acquisition of CL, especially for adventure travelers on 
long-term trips in highly endemic forested areas, is 
South America, whereas popular Mediterranean 
destinations are emerging as the main areas to acquire 
the visceral variant. The management of these 
infections in developed, non-endemic countries is still 
difficult owing to the unfamiliarity of physicians with 
clinical syndromes, diagnostic possibilities, and 
available treatment options. Therefore, travelers and 
other people who could be exposed to sand flies in 
endemic areas should receive counseling regarding 
leishmaniasis and appropriate protective measures. 
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Diagnosis 
Most VL infections are diagnosed clinically with 
observation of irregular fever, anemia, leucopenia, and 
hepatosplenomegaly [2], but there are several methods 
of laboratory diagnosis of leishmaniasis. As recently 
reported [25], these include parasite detection by 
microscopic examination, culture and successive 
isoenzyme analysis for identification, or molecular 
biology-based assays for detecting the parasite DNA 
(polymerase chain reaction [PCR]). These last tests are 
more sensitive, but may be applied only in particular 
centers. Different PCR methods have been evaluated 
[26,27] and have been found to demonstrate a superior 
sensitivity compared with microscopy smear and in 
vitro culture. 
Serological diagnosis, even if rarely used for CL 
and mucocutaneous leishmaniasis (MCL) disease, is 
the technique more commonly used for VL [25]. 
Various techniques are employed, including 
Immunofluorescence antibody assay (IFA), enzyme-
linked immunosorbent assay (ELISA), western blot, 
rapid strip testing for rK39 antigen, direct 
agglutination technique, or detection of Leishmania 
antigen in urine by latex agglutination. High serum 
antibody levels are present in both asymptomatic and 
active VL and remain present for several years. 
However, the specificity of these tests in VL-endemic 
areas is variable, and in Leishmania/HIV co-
infections, the serological approach for diagnosis is 
difficult owing to the immunosuppressive action of the 
virus. In fact, in these cases, additional molecular or 
other parasitological tests may be necessary if the 
results of the serological tests are negative. 
Mohapatra et al. [28] conducted a comparative 
evaluation of different recombinant antigens for the 
serodiagnosis of Indian visceral leishmaniasis. They 
concluded that rK39 (a 39-aminoacid-repetitive 
immunodominant B-cell epitope of kinesin-related 
antigen from L. chagasi) was the most suitable antigen 
when compared with rK26 and rK9; this last antigen 
may be used as an adjunct to rK39 for accurate 
diagnosis of VL. The diagnostic antigens rK26 and 
rK18 were demonstrated to be suitable to be used as an 
indirect measure of parasite clearance after therapy 
[29]. The ELISA technique effected with a 
recombinant L. infantum heat shock protein 83 
(rHsp83) represents a routine confirmatory serological 
assay for the diagnosis of CL, MCL, and VL [30]. 
Integrated diagnosis based on clinical symptoms 
together with an rK39 immunochromatographic rapid 
test is commonly used, whereas a combination of 
molecular and serological tests are especially useful 
for asymptomatic infections in endemic areas [25]. 
Leishmaniasis should be considered in the diagnostic 
assessment of patients with a compatible clinical 
syndrome and a history of traveling in an endemic 
area, even if it occurred several months or years before 
[21]. 
 
Treatment 
The drugs employed to treat VL are expensive and 
sometimes have toxic side effects. 
A recent review of new chemotherapeutic 
strategies against malaria, leishmaniasis, and 
trypanosomiasis [31], reports the updated literature on 
the challenges of drugs against leishmaniae. 
Liposomal amphotericin B has the best safety 
profile and has been approved by the Food and Drug 
Administration (FDA) for the treatment of VL [32] 
and is the drug most used in species-directed therapy 
of leishmaniasis in returning travelers [33].  
A multicenter, open-label study evaluated the 
efficacy and safety of two treatment options,  single 
infusion of preformed amphotericin B (AmB) lipid 
emulsion (ABLE) and liposomal formulation (LAmB); 
the first type of infusion was found to be more 
effective and better tolerated [34]. Resveratrol, a 
polyphenol found in black grapes and red wine that 
has many biological activities, in association with 
amphotericin B, showed synergy against L. 
amazonensis in vitro [35]. 
Other drugs that have been brought onto the 
market more recently are paromomycin and 
miltefosine. The first is an aminoglycoside antibiotic, 
which was granted orphan drug status in 2005, and is 
used for the treatment of both VL and CL in parenteral 
and topic formulations [36]. Miltefosine was 
registered in India in 2002 as the first oral 
antileishmanial agent; its major limitations are the 
high cost, the need for monitoring of gastrointestinal 
side-effects, and occasional hepatic and renal toxicity 
[37]. Combining paromomycin with miltefosine, the 
release of nitric oxide and tumour necrosis factor by 
human macrophages was induced, enhancing the 
killing of L. donovani promastigotes in vitro [38]. 
Fexinidazole (formerly Hoe 239), an oral 
nitroimidazole, was rediscovered by the Drugs for 
Neglected Disease initiative (DNDi) and is in clinical 
trials for the treatment of African sleeping sickness; 
this compound or another nitroimidazole, PA-824, 
may be effective against leishmaniae [39]. 
The synthesis of polyamines and of their 
precursors is essential for Leishmania protozoa; 
therefore, the enzymes involved in spermidine 
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synthesis and utilization, in particular trypanothione 
synthetase and trypanothione reductase, are attractive 
targets for drug development [40]. 
Also, peptidases (proteases) are enzymes that are 
considered interesting targets for chemotherapy 
[31,41]. The only aspartic protease present in 
leishmaniae belongs to the family of the A2 retroviral-
like aspartic proteases and is inhibited by drugs 
originally developed as inhibitors of HIV protease 
[42,43]. A recent review [42] summarizes the biology 
of kinetoplastid topoisomerases, which can be 
molecular targets in antileishmanial chemotherapy, as 
observed with pefloxacin in 1996 [45]. 
In Leishmania, dihydrofolate reductase (DHFR) 
forms a functional complex with thymidylate synthase 
(TS). By means of an in silico virtual screening 
technique, many DHFR-TS based drugs were 
screened; among these, the molecule 571633 proved 
promising and deserves further development [46]. 
High-throughput screening has also been used to 
identify molecules based on new molecular scaffolds. 
CA272 and CH872 are two molecules, based on the 
hydrazine and 4-hydroxyquinoline scaffolds, 
respectively, that are new promising antileishmanial 
compounds [47]. 
Prati et al. [48] investigated the feasibility of 
targeting Leishmania transporters via appropriately 
designed chemical probes. L. donovani is auxotrophic 
for arginine and lysine and has specific transporters 
(LdAAP3 and LdAAP7) to import these nutrients. 
Some conjugates containing cytotoxic quinone 
fragments (II and III) linked to amino acids (arginine 
and lysine) displayed toxicity against the parasites and 
not against mammalian THP1 cells. Recently, Nagle et 
al. [49] reported significant progress in the treatment 
of both leishmaniasis and African trypanosomiasis 
(HAT). However, new drugs for both diseases are still 
needed; two compounds were in clinical trials for 
HAT (nifurtimox and SCYX-7158) and one for VL 
(nifurtimox). Gupta et al. [50] recently identified a 
nitroimidazo-oxazole lead molecule for the treatment 
of VL. In particular, the compound DNDI-VL-2098 
was characterized by a leishmanicidal activity and a 
capacity of inducing host-protective immune cells in 
hamsters. Moreover, some novel heteroretinoid-
bisbenzylidine ketone hybrids have been synthesized 
and evaluated by Tiwari et al. [51] for their in vitro 
activity against L. donovani; a new class of 
compounds with antileishmanial activity was 
identified. Also, N-substituted β-amino alkanols were 
recently shown to have leishmanicidal activity, 
inducing severe mitochondrial swelling and 
vesiculation of the parasite [52]. 
A new delivery strategy that can increase drug 
distribution among different mononuclear phagocyte 
system tissues was studied [53]; pegylated meglumine 
antimoniate-containing liposomes (LMA) and their 
mixture with non-pegylated (conventional) LMA 
proved to be more effective in dogs and mice than did 
conventional LMA against VL. Crovirin, a cysteine-
rich secretory protein (CRISP), extracted from 
Crotalus viridis viridis snake venom, used with a high-
performance liquid chromatographer, had promising 
results against trypanosomes and leishmania [54]. This 
family might have potential as drugs or drug leads for 
the development of novel agents against these 
protozoa. 
Different natural products were assessed. De 
Queiroz et al. [55] investigated the leishmanicidal 
activity of five species of plants used in folk medicine 
in Brazil in patients with CL (L. amazonensis). The 
plant extracts Hyptis pectinata (L.) Poit, Aloe vera 
(L.), Ruta graveolens (L.), Pfaffia glomerata (Spreng) 
Pedersen, and Chenopodium ambrosioides (L.) 
exhibited direct activity against extracellular forms of 
Leishmania. Recently, thymol derivatives were 
assessed in mice, and were found to demonstrate 
greater activity than the eugenol derivatives; benzoyl-
thymol was the best inhibitor with decreased toxicity 
[56]. These modified compounds are promising 
candidates for further studies of antileishmanial drug 
development. The leishmanicidal effect of essential oil 
from Artemisia annua leaves against L. donovani in 
vitro and in vivo was also reported [57]. 
Nadhman et al. [58] described daylight responsive 
silver (Ag) doped semiconductor nanoparticles of zinc 
oxide for photodynamic therapy (PDT) against 
Leishmania. These biocompatible nanoparticles 
demonstrated a daylight response, causing 
permeability of the cell membrane and the death of 
parasites. Daylight-activated photodynamic therapy 
(DA-PDT), which abolishes the need for artificial light 
sources, permitting auto-treatment of the patient, was 
found to be effective for CL caused by L. major and L. 
tropica [59]. Different macrocycles, i.e., cyclic 
macromolecules, such as sapphyrin and two related 
heterosapphyrins, have been investigated as potential 
agents for the treatment of leishmaniasis [60]. 
 
Immunity and immunotherapy 
Vaccination to control leishmaniasis is promising, 
but at the moment, no human vaccine is commercially 
available due to different causes, but particularly due 
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to the complexity of the cellular immune response to 
this parasite [2]. Vaccines against canine 
leishmaniasis, for the reduction of the transmission of 
L. infantum to people, have been tested in Brazil and 
Europe with mixed results. A recent study showed that 
first-generation canine vaccines have inadequate 
ability to produce long-lasting immunity [61]. Third-
generation vaccines are protective, but owing to the 
different nature of DNA antigens, their value is 
unclear. Second-generation vaccines could be one of 
the best choices for canine Leishmania vaccination. 
They consist of L. donovani glycoprotein (fucose 
mannose ligand) with saponin as an adjuvant. 
Recently, Gradoni [60] demonstrated that an effective 
canine Leishmania vaccine should induce strong and 
long-lasting Th1-dominated immunity to control both 
infection progression and parasite transmissibility via 
the vector. Promising antigens, including killed 
parasites, cell purified fractions, parasite protein 
components or subunits, single or multiple chimeric 
recombinant proteins, plasmid DNA and viral particles 
encoding parasite virulence factors, and adjuvant 
combinations have been tested on dogs. Limited or no 
protection was observed in phase I and II studies. The 
A2 antigen (a recombinant protein from the amastigote 
stage of different Leishmania species) plus saponin, 
which gave about 40% protection against infection, 
has been registered as a canine vaccine, LeishTec in 
Brazil and CaniLeish in Europe. 
Prophylactic vaccination of both human VL 
carriers and dogs could generate long-term protection, 
reducing disease incidence. Therefore, different 
studies [63,64] continue to refine both antigen and 
adjuvant components of vaccines, as well as identify 
the mechanisms associated with immune evasion and 
disease progression to develop novel vaccine 
approaches. Leishmania parasites activate the innate 
and adaptive arms of the immune system, and a 
coordinated network of responses is required for 
effective immune-mediated parasite clearance. In 
particular, one of the reasons for anti-leishmaniasis 
vaccine failure is the lack of an appropriate adjuvant. 
Chemokine and cytokine responses are essential; 
however, Leishmania parasites have developed 
numerous mechanisms to prevent the development of 
immunity; one of these is inducing 
immunosuppressive cytokines. Recently, different 
methodologies, which include proteomics, have 
identified new antigens for potential polyvalent 
synthetic and recombinant chimeric vaccine 
candidates [65]. 
VL pathogenesis has been correlated with an 
overproduction of the regulatory cytokine IL-10, 
responsible for disease progression, whereas cytokines 
that selectively induce Th1 responses might be useful 
for VL therapy [66]. Also, dendritic cells are important 
in initial anti-Leishmania T cell responses, promoting 
the differentiation into memory T cells. Dendritic cell-
based immunotherapy combined with antimony-based 
chemotherapy has been studied in mice, revealing a 
promising synergy. The IFNγ released by cells, 
particularly by CD+ T cells, from VL patients serves 
to limit parasite growth [67]. Arabinosylated 
lipoarabinomannan, a Toll-like receptor 2-ligand 
isolated from Mycobacterium smegmatis, has a strong 
immunomodulatory property, giving protection against 
L. donovani infection by restoring IFN-γ 
responsiveness important for protection against L. 
donovani-susceptible hosts [68]. The role of 
interleukin 17 (IL-17), an inflammatory cytokine that 
plays a protective role against intracellular parasites, is 
controversial. Nascimento et al. [67], evaluating the 
levels of IL-17A in the sera from patients with VL 
before and at different times  after treatment with 
Glucantime, noted higher levels in the sera of patients 
with VL before treatment than in normal or endemic 
controls; during treatment, the levels of IL-17A 
decreased, but remained significantly higher than the 
values of normal subjects. This cytokine acts 
synergistically with IFN-γ, increasing nitric oxide 
production and leishmanicidal activity in infected 
macrophages. Tumor necrosis factor α (TNF-α) is 
another cytokine that is important in Leishmania 
infections, controlling inflammatory lesions and 
parasite killing. A new strategy for leishmanial 
treatment is based also on Toll-like receptor signal 
pathways [70].  
Though vitamin A supplementation proved to be 
effective in diarrheal and respiratory diseases in 
several countries, few studies examined the effect in 
VL. Lima Maciel et al. [69] analyzed the effect of this 
vitamin on regulatory T cells and monocytes isolated 
from symptomatic VL and from healthy children 
residing in an area endemic for VL; they demonstrated 
that vitamin A associated to VL therapy improved 
recovery. 
Kaur et al. [70] recently studied herbal drugs 
derived as whole-plant extracts of Asparagus 
racemosus and Withania somnifera to treat L. 
donovani-infected BALB/c mice. Treatment with both 
extracts in combination was found to be effective 
against parasites, generating protective Th1-type 
immune responses. 
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To identify new immunogens as vaccines in a 
murine model of VL, epitope-based immunogens, 
consisting of phage-fused peptides mimicking L. 
infantum antigens, were selected, and their affinity to 
antibodies from asymptomatic and symptomatic VL 
dogs’ sera was studied [71]. Two phage clones 
expressing target mimotopes provided protection in 
mice against L. infantum correlated to a Th1-type 
immune response. 
Previously, it was reported that liposomes 
associated with amphotericin B were used for 
Leishmania therapy [32]. Moreover, they have been 
found to be potent adjuvants for different antigens and 
are effective vehicles for peptides and proteins, 
increasing their immunogenicity. Liposomes carrying 
glycosylphosphatidylinositol-anchored proteins of L. 
amazonensis promastigotes could, in fact, induce 
protective immunity in mice [72]. 
 
Conclusions 
Leishmaniasis is a major health problem 
worldwide. The spectrum of infection is subclinical 
(not apparent), localized (skin lesion), and 
disseminated (mucocutaneous and visceral); it depends 
on the immune status of the host, on the parasite, and 
on immune-inflammatory responses. 
Major risk factors of Leishmania distribution are 
socioeconomic conditions, malnutrition, population 
mobility, and environmental and climate changes. 
Prevention and control are based on early diagnosis 
and treatment, vector control, disease surveillance, and 
education of the community. The European Union has 
been receiving, since the mid-1900s, an influx of 
immigrants, known to be a marginalized and 
vulnerable group, with an estimated 20 million 
migrants having arrived in the past 15 years [3]. 
Therefore, leishmaniasis should be considered in the 
diagnostic assessment of immigrants or travelers who 
could have been exposed to the parasite in endemic 
areas [24,25]. 
This protozoan disease is second to malaria in 
importance for human health; however, the options for 
chemotherapeutic treatment are limited owing to drug 
resistance and toxicity. The drug of choice is still out 
of reach; among the chemotherapeutic strategies, the 
combination of local and parenteral therapies could be 
more effective, shortening the duration of the 
treatment. A new strategy, studied in vitro, is based on 
nanoemulsions containing cholesterol and 
amphotericin B; the encapsulation of the drug seems to 
increase its efficiency [73]. 
To combat VL, it is important to unite groups 
working on drugs for the disease into a single 
organization, the VL Global R&D & Access Initiative 
[74].  
For immunity to Leishmania antigen, persistence is 
necessary [64]. L. major vaccine consisting of  needle 
inoculation with viable L. major parasites in a selected 
site, referred to as leishmanization, has been used in 
the past for people living in regions endemic for 
cutaneous forms of leishmaniasis. This is not a vaccine 
in the conventional sense, even if the cultures were 
less virulent than the forms inoculated by the sand-fly 
vector. Its use was interrupted owing to severe primary 
lesions. Irradiated or genetically modified organisms 
could be used for immunization; however, priority 
should be given to clinical trials of defined, subunit 
vaccines against this parasitic disease. Promising 
antigens, single or multiple chimeric recombinant 
proteins, plasmid DNA and viral particles encoding 
parasite virulence factors, and adjuvant combinations 
have been tested. Prophylactic and immunotherapy 
vaccination of both humans and dogs could generate 
long-term protection, reducing disease incidence 
responsible for protean manifestations. 
 
 
Dedication 
This paper is dedicated to Prof. Piero Cappuccinelli, a 
brilliant scientist, teacher and friend. Piero is well-known 
worldwide as a visiting teacher in different prestigious 
institutions of several countries and for various projects. He 
has been a curious, eclectic and inventive scientist since his 
training in Microbiology and Parasitology at the University 
of Turin. I am proud to know him not only as a scientist and 
colleague but also as a friend. 
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